EU/3/06/371

Table of contents

About

On 22 May 2006 orphan designation (EU/3/06/371) was granted by the European Commission to Ockham Biotech Limited, United Kingdom, for heparin sodium for the treatment of cystic fibrosis.

The sponsorship was transferred to Ockham Biotech Ireland Limited, Ireland in May 2019.

Key facts

Active substance
Heparin sodium
Disease / condition
Treatment of cystic fibrosis
Date of first decision
22/05/2006
Outcome
Positive
EU designation number
EU/3/06/371

Sponsor's contact details

Ockham Biotech Ireland Limited
17 Corrig Road
Sandyford Industrial Estate
Dublin 18
Co. Dublin D18 N6K8
Ireland
Tel. +353 1634 9590
E-mail: as@ockhambiotech.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Cystic Fibrosis Trust
    11 London Road
    Bromley
    Kent
    BR1 1BY
    United Kingdom
    Telephone: +44 20 84 64 72 11
    Telefax: +44 20 83 13 04 72
    E-mail: enquiries@cftrust.org.uk
  • Cystische Firbose Hilfe Österreich
    Hanuschgasse 1
    2540 Bad Vöslau
    Austria
    Telephone: +43 2252 89 00 18
    Telefax: +43 2252 89 00 18 15
    E-mail: office@cf-austria.at
  • Vaincre la Mucoviscidose
    181, rue de Tolbiac
    75013 Paris
    France
    Telephone : +33 1 40 78 91 91
    Telefax : +33 1 45 80 86 44
    E-mail : info@vaincrelamuco.org

How useful was this page?

Add your rating